Skip to main content
Clinical Trials/KCT0008610
KCT0008610
Recruiting
未知

A multi-center, prospective observational study to evaluate the effectiveness of a single-pill combination of amlodipine, losartan, rosuvastatin, and ezetimibe in patients with hypertension and dyslipidemia

Pusan National University Yangsan Hospital0 sites550 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Pusan National University Yangsan Hospital
Enrollment
550
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Patient diagnosed with essential hypertension and primary hypercholesterolemia, scheduled for treatment with a combination medication containing amlodipine, losartan, rosuvastatin, and ezetimibe.
  • 2\.Patient diagnosed with essential hypertension or primary hypercholesterolemia, currently receiving treatment with antihypertensive or lipid\-lowering medications, planning to switch to a combination medication containing amlodipine, losartan, rosuvastatin, and ezetimibe.

Exclusion Criteria

  • 1\.According to the approval indications, the combination medication containing losartan and amlodipine should not be administered in cases where there are contraindications specified.
  • 2\.The statin class medications (such as rosuvastatin, atorvastatin) and ezetimibe should not be administered in cases where there are contraindications specified.
  • 3\.Patients with suspected secondary hyperlipidemia or secondary hyperlipidemia, such as nephrotic syndrome, proteinuria, obstructive liver disease, Cushing's syndrome, etc.
  • 4\.If the patient has received investigational drugs for clinical trials within 4 weeks prior to the registration date, or plans to participate in other clinical trials during the study period.

Outcomes

Primary Outcomes

Not specified

Similar Trials